Multilaboratory Evaluation of Real-Time PCR Tests for Hepatitis B Virus DNA Quantification

Angela M. Caliendo  
*Emory University*

Alexander Valsamakis  
*Johns Hopkins University*

James W. Bremer  
*Rush University*

Andrea Ferreira-Gonzalez  
*Virginia Commonwealth University*

Suzanne Granger  
*New England Research Institutes, Inc.*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.dartmouth.edu/facoa](https://digitalcommons.dartmouth.edu/facoa)

Part of the *Infectious Disease Commons, and the Medical Microbiology Commons*

**Dartmouth Digital Commons Citation**

Caliendo, Angela M.; Valsamakis, Alexander; Bremer, James W.; Ferreira-Gonzalez, Andrea; Granger, Suzanne; Sabatini, Linda; and Tsongalis, Gregory J., "Multilaboratory Evaluation of Real-Time PCR Tests for Hepatitis B Virus DNA Quantification" (2011). *Dartmouth Scholarship*. 1215.  
[https://digitalcommons.dartmouth.edu/facoa/1215](https://digitalcommons.dartmouth.edu/facoa/1215)

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.
Multilaboratory Evaluation of Real-Time PCR Tests for Hepatitis B Virus DNA Quantification

Angela M. Caliendo,1‡* Alexander Valsamakis,2† James W. Bremer,3 Andrea Ferreira-Gonzalez,4 Suzanne Granger,5 Linda Sabatini,5‡ Gregory J. Tsongalis,7 Yun F. (Wayne) Wang,8 Belinda Yen-Lieberman,9 Steve Young,10 and Nell S. Lurain3

Department of Pathology and Laboratory Medicine, Emory University School of Medicine and Emory Center for AIDS Research, Emory University, Atlanta, Georgia; Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland; Department of Immunology/Microbiology, Rush University Medical College, Chicago, Illinois; Department of Pathology, Virginia Commonwealth University, Richmond, Virginia; New England Research Institutes, Inc., Watertown, Massachusetts; Department of Pathology, ACL Laboratories, Rosemont, Illinois; Department of Pathology, Dartmouth Medical School, Lebanon, New Hampshire; Pathology and Laboratory Medicine, Emory University School of Medicine, Grady Memorial Hospital, Atlanta, Georgia; Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio; and Tricore Reference Laboratories, Albuquerque, New Mexico, and Department of Pathology, University of New Mexico HSC, Albuquerque, New Mexico.

Received 7 March 2011/Returned for modification 17 April 2011/Accepted 10 June 2011

The performance characteristics of four different assays for hepatitis B virus (HBV) quantification were assessed: the Abbott RealTime HBV IUO, the Roche Cobas AmpliPrep/Cobas TaqMan HBV test, the Roche Cobas TaqMan HBV test with HighPure system, and the Qiagen artus HBV TM ASR. Limit of detection (LOD), linear range, reproducibility, and agreement were determined using a serially diluted plasma sample from a single chronically infected subject. Each assay was tested by at least three laboratories. The LOD of the RealTime and two TaqMan assays was approximately 1.0 log_{10} IU/ml for artus HBV (which used the lowest volume of extracted DNA), it was approximately 1.5 log_{10} IU/ml. The linear range spanned 1.0 to at least 7.0 log_{10} IU/ml for all assays. Median values were consistently lowest for artus HBV and highest for Cobas AmpliPrep/Cobas TaqMan HBV. Assays incorporating automated nucleic acid extraction were the most reproducible; however, the overall variability was minor since the standard deviations for the means of all tested concentrations were ≤0.32 log_{10} IU/ml for all assays. False-positive results were observed with all assays; the highest rates occurred with tests using manual nucleic acid extraction. The performance characteristics of these assays suggest that they are useful for management and therapeutic monitoring of chronic HBV infection.

Hepatitis B virus (HBV) has infected an estimated 400 million persons worldwide; cirrhosis and hepatocellular carcinoma, the major sequelae of chronic hepatitis B, result in over a half million deaths annually (4). HBV viremia is a critical risk factor for progression of chronic HBV infection (1); accordingly, quantification of HBV DNA in blood has become a critical tool in the assessment and management of chronic infection. In addition to serologic tests for HBV and measurement of serum transaminases, HBV viral load testing is used to determine the phase of chronic HBV infection (8) and is particularly useful in distinguishing active from inactive disease in individuals with no detectable HBeAg. A number of antiviral drugs have been introduced recently for the treatment of chronic HBV infection, and viremia is an important component in the decision to initiate treatment and in monitoring therapeutic response (5, 7).

Viremia in chronic HBV infection varies from very low or undetectable to >10^8 copies/ml. Effective quantitative assays must therefore measure a wide range of viral DNA concentrations. Commercially available quantitative assays utilize a variety of different detection methods, including signal amplification (Versant HBV bDNA; Siemens Healthcare Diagnostics), conventional PCR (Amplipcr HBV Monitor test; Roche Diagnostics), and real-time PCR (Cobas AmpliPrep/Cobas TaqMan HBV test [Roche Diagnostics] and RealTime HBV assay [Abbott Molecular]). Of these methods, only real-time PCR is able to cover the wide dynamic range required for quantification of the virus in all stages of infection.

Reported studies of real-time assays have mainly focused on the performance of individual tests compared to signal amplification tests rather than the comparative performance of multiple real-time PCR tests (2, 3, 6, 9). The present study assessed the limit of detection, linear range, reproducibility, and agreement among four commercially available real-time PCR HBV viral load tests: the Abbott RealTime HBV IUO, the Roche Cobas AmpliPrep/Cobas TaqMan HBV test, the Roche Cobas TaqMan HBV test with HighPure system, and the Qiagen artus HBV TM ASR. The Abbott m2000sp and Roche AmpliPrep protocols were performed using automated extraction methods, while the extractions for the Roche HighPure and Qiagen ASR were performed manually.
MATERIALS AND METHODS

Quantification panels. A 65-specimen panel was created to be used by participating laboratories to assess assay performance. The panel was created in a centralized laboratory (the Division of AIDS Viral Quality Assurance Laboratory, Rush University Medical Center, Chicago, IL) by serially diluting a unit of plasma obtained from a patient donor infected with HBV. The diluent was human plasmapheresis plasma containing the anticoagulant sodium citrate (SeraCare, Milford, MA) and found to be negative for HBsAg by serologic testing; this also served as negative sample material. HBV-infected donor blood was obtained under an institutional review board-approved protocol. The plasma was assigned a nominal concentration of 8.58 log_{10} IU/ml of genotype A virus as determined by Versant HBV DNA 3.0 (Siemens, Hoffman Estates, IL). Four replicates of each of three different dilutions (1:100, 1:1,000, and 1:10,000) were tested to determine IU/ml.

HBV genotype was determined by direct sequencing of the polymerase gene (nucleotides 1 to 1615 and 2528 to 3221 of the circular genome) with QIAamp MinElute Virus Spin kit manual sample preparation (Qiagen, Germantown, MD). Four replicates consisted of 5 to 7 replicates of 10 concentrations ranging from 1.0 to 7.7 log_{10} IU/ml each in a volume of 750 μl (Table 1). Panel members were tested in a blinded manner by participating laboratories.

Viral load assays. Four HBV viral load assays were evaluated, including RealTime HBV EVO with m2000sp automated sample preparation (Abbott Molecular, Des Plaines, IL), TaqMan48 HBV ASR with AmpliPrep automated sample preparation (Roche Diagnostics, Indianapolis, IN), TaqMan HBV RUO with HighPure system manual sample preparation (Roche), and artus HBV TM ASR with QIAamp MinElute Virus Spin kit manual sample preparation (Qiagen, Germantown, MD). The plasma extraction volume was 500 μl for each assay, while the amplification mixtures for the two TaqMan assays and the RealTime assay contained 1.5 μl of master mix for a total amplification volume of 50 μl. Amplification and quantification were performed per package insert if available; otherwise, protocols were developed in collaboration with manufacturers’ research and development expertise.

RESULTS

The detection rates of the different tests are summarized in Table 2. All tests were highly sensitive, with the RealTime, AmpliPrep TaqMan, and High Pure TaqMan assays qualitatively detecting all 27 or 28 replicates of the 1.0 log_{10} IU/ml sample. The artus HBV test detected 24/28 1.0 log_{10} IU/ml replicates and all 28 replicates of the 1.5 log_{10} IU/ml sample. Although false-positive results occurred with all of the assays, they were seen more frequently in the assays that used manual extraction methods (4/28 for the HighPure TaqMan test and 5/28 for the artus HBV assay, compared to 1/28 for the Real-Time and 2/28 for the AmpliPrep TaqMan assays). False-positive results were not confined to any one laboratory; 50% of the false-positive results were from samples that were adjacent to a sample with a very high viral load (>10 million IU/ml).

The median viral load values and intraquartile ranges for the four viral load assays are shown in Table 3. Overall, there was good agreement in viral load values between the assays. For samples with a nominal concentration ranging from 1.5 log_{10} IU/ml to 7.0 log_{10} IU/ml, the differences in the median viral load values across the four assays were between 0.29 log_{10} IU/ml and 0.56 log_{10} IU/ml. The samples with nominal concentrations of 1.0 log_{10} IU/ml and 7.7 log_{10} IU/ml were not analyzed because values were not available for all four assays. The standard deviations of the mean viral load values are shown in Table 4. In most instances, lower standard deviations were observed at concentrations greater than 2.0 log_{10} IU/ml. All assays were linear to 7.7 log_{10} IU/ml with the exception of the AmpliPrep TaqMan assay, as all 7.7 log_{10} IU/ml values were above the upper linear range of the assay (8.04 log_{10}
IU/ml) and were reported as such by the TaqMan instrument (Fig. 1).

The assay bias, expressed as log_{10} IU/ml viral load values minus the nominal concentration, is shown in Fig. 2. The RealTime assay showed very consistent bias for samples greater than or equal to 3.0 log_{10} IU/ml. The AmpliPrep TaqMan assay consistently gave the highest viral load values, and there was variable bias throughout the linear range of the assay. A similar pattern of bias was seen with the HighPure TaqMan assay, although the values were lower than those seen with the AmpliPrep TaqMan assay. The artus HBV assay showed consistent bias for samples above 2.0 log_{10} IU/ml and overall showed the lowest viral load values.

**DISCUSSION**

This comparison of four real-time PCR assays demonstrated that they have very similar performance characteristics, although some differences were noted. For example, the two TaqMan and the RealTime assays had a lower limit of detection of 1.0 log_{10} IU/ml, compared to 1.5 log_{10} IU/ml for the artus HBV assay. This minor difference is likely due to plasma input volume differences between artus HBV (200 µl) and the other assays (500 µl). In addition, a lower percentage of the extracted DNA was added to the master mix with the artus HBV assay compared to the other three assays (33% versus ~70%). Despite this analytical difference, all assays had detection limits within the necessary range for clinical decision making.

Another difference that was observed pertained to false-positive rates. Assays that relied on manual extraction (HighPure TaqMan and artus HBV) had higher false-positive rates than did those that employed automated extraction (RealTime and AmpliPrep TaqMan assays). The occurrence of false-positive results with automated extraction platforms is an important observation that may reflect the performance expected in the clinical laboratory, where samples with viral load values in excess of 8.0 log_{10} IU/ml may be tested alongside samples containing no virus. These data suggest that regardless of the extraction method employed, careful attention to good laboratory practices will be needed to avoid false-positive results due to the extraordinarily high viral loads that occur in chronic HBV infections.

All four assays demonstrated a broad linear range of approximately 7 log_{10} IU/ml; we were unable to obtain a large-volume sample with a higher viral load to better define the upper limits of linearity of the assays. Quantification of the 7.7-log_{10} IU/ml sample resulted in concentrations that exceeded the upper limit of the AmpliPrep TaqMan assay but not those of the other three assays. According to the AmpliPrep TaqMan package insert, it would have been acceptable to dilute these high-concentration samples up to 1:100 in order to report out a value up to 10.23 log_{10} IU/ml; however, specimen dilution was not part of the study protocol and, therefore, it was not performed. This approach is appropriate for all of the assays as long as the dilution process is validated by the laboratory.

The reproducibility of the assays was similar to that seen with other real-time PCR tests. For viral load values in the middle of the linear range where the standard deviations are 0.05 to 0.10 log_{10} IU/ml, a change in viral load that is greater than 3-fold would be interpreted to be a significant difference. For viral load values less than 2.0 log_{10} IU/ml, where the standard deviation is higher, 5-fold changes would be significant. Overall, the artus HBV assay was the least precise of the four assays evaluated; this may in part reflect the manual extraction method.

The differences in the median viral load values obtained with

**TABLE 3. Median viral load values and intraquartile ranges**

<table>
<thead>
<tr>
<th>Log_{10} nominal concn (IU/ml)</th>
<th>Median (Q1, Q3)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RealTime HBV</td>
</tr>
<tr>
<td>1.0</td>
<td>1.18 (1.10, 1.34)</td>
</tr>
<tr>
<td>1.5</td>
<td>1.57 (1.52, 1.73)</td>
</tr>
<tr>
<td>2.0</td>
<td>2.02 (1.96, 2.13)</td>
</tr>
<tr>
<td>2.5</td>
<td>2.44 (2.40, 2.49)</td>
</tr>
<tr>
<td>3.0</td>
<td>2.89 (2.80, 2.93)</td>
</tr>
<tr>
<td>4.0</td>
<td>3.85 (3.84, 3.90)</td>
</tr>
<tr>
<td>5.0</td>
<td>4.87 (4.83, 4.92)</td>
</tr>
<tr>
<td>6.0</td>
<td>5.91 (5.86, 5.94)</td>
</tr>
<tr>
<td>7.0</td>
<td>6.93 (6.89, 6.96)</td>
</tr>
<tr>
<td>7.7</td>
<td>7.66 (7.61, 7.69)</td>
</tr>
</tbody>
</table>

* Nineteen of 28 samples reported as “detected, <6 IU/ml.”

**TABLE 4. Standard deviations of the mean viral load values**

<table>
<thead>
<tr>
<th>Log_{10} nominal concn (IU/ml)</th>
<th>RealTime HBV</th>
<th>AmpliPrep TaqMan HBV</th>
<th>HighPure TaqMan HBV</th>
<th>artus HBV TM ASR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>SD</td>
<td>n</td>
<td>SD</td>
</tr>
<tr>
<td>1.0</td>
<td>28</td>
<td>0.19</td>
<td>28</td>
<td>0.22</td>
</tr>
<tr>
<td>1.5</td>
<td>28</td>
<td>0.13</td>
<td>28</td>
<td>0.11</td>
</tr>
<tr>
<td>2.0</td>
<td>28</td>
<td>0.08</td>
<td>28</td>
<td>0.13</td>
</tr>
<tr>
<td>2.5</td>
<td>20</td>
<td>0.09</td>
<td>19</td>
<td>0.11</td>
</tr>
<tr>
<td>3.0</td>
<td>20</td>
<td>0.10</td>
<td>18</td>
<td>0.10</td>
</tr>
<tr>
<td>4.0</td>
<td>20</td>
<td>0.06</td>
<td>20</td>
<td>0.10</td>
</tr>
<tr>
<td>5.0</td>
<td>20</td>
<td>0.05</td>
<td>20</td>
<td>0.09</td>
</tr>
<tr>
<td>6.0</td>
<td>20</td>
<td>0.07</td>
<td>20</td>
<td>0.11</td>
</tr>
<tr>
<td>7.0</td>
<td>20</td>
<td>0.10</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

a All 20 samples reported as >8.04 log_{10} IU/ml.

b Three samples reported as >8.04 log_{10} IU/ml.

**Note:** All 20 samples reported as >8.04 log_{10} IU/ml.
the four assays ranged from 0.29 log_{10} IU/ml to 0.56 log_{10} IU/ml. The smallest difference was seen for the 6.0-log_{10} IU/ml sample, and the largest difference was seen for the 3.0-log_{10} IU/ml sample. The most consistent bias (difference between nominal concentration and observed concentration) was seen with the artus HBV assay for values of >2.0 log_{10} IU/ml and with the RealTime assay for values of ≥3.0 log_{10} IU/ml. Both TaqMan assays showed an inconsistent bias throughout the linear range of the assays. One limitation of this study is that only a genotype A sample was studied, so it is not possible to determine if any of these assays has a genotype bias.

The availability and regulatory status of the investigated assays have changed since the conclusion of experimentation. The artus HBV assay is available outside the United States as a Conformité Européenne (CE)-marked product. The RealTime and TaqMan reagents have been approved for use by the U.S. Food and Drug Administration (U.S. FDA) and are CE marked. Plasma volumes identical to those used in this study are used in the U.S. FDA-approved assays. The RealTime assay is additionally approved for use with 200 µl of plasma. Comparative performance of the assay with this reduced volume was not investigated in this study.

Though there is reasonable agreement in viral load values across the four assays, the intra-assay and between-assay variability are such that patients should be monitored with a single assay. False positives were observed on all platforms, and care-

FIG. 1. Linear range of the viral load assays.

FIG. 2. Assay bias of the four real-time PCR assays for HBV quantification. Bias is defined as measured viral load (log_{10} IU/ml) minus the nominal concentration of the sample (log_{10} IU/ml).
ful attention should be paid to avoid cross-contamination by samples that may contain extremely high concentrations of this virus.

In summary, all four assays are similarly sensitive and have a broad linear range, providing clinical utility for both diagnostic testing and therapeutic monitoring.

ACKNOWLEDGMENTS

Assay reagents for this study were generously supplied by the manufacturers. We thank Michael S. Forman, Jess Ingersoll, Salvatore Scianna, Heather B. Steinmetz, Debra Kohn, Stephanie Merritt, Najma Akbany, and Ray Mills for their expert technical assistance.

This work was supported in part by National Institutes of Health contract NO1-AI35172 to J.W.B., an Emory University Center for AIDS Research grant (P30 AI050409, A.M.C.), and the HIV Prevention Trials Network (HPTN) sponsored by the NIAID, National Institutes of Child Health and Human Development (NICHD), National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, DHHS (U01-AI-46745 and U01-AI-068613 to A.V.).

Disclosures of potential conflicts of interest include the following: A.M.C., scientific advisory boards of Roche Diagnostics and Abbott Molecular and research support from Roche Diagnostics and Qiagen; S.Y., scientific advisory board of Roche Diagnostics; A.V., scientific advisory boards of Roche Diagnostics, Abbott Molecular, and Qiagen and research support from Roche Diagnostics and Qiagen; L.S., speaking honorarium from Abbott Molecular.

REFERENCES